NASDAQ · CUE
Cue Biopharma, Inc.
$21.45+$0.29 (+1.37%)
Cue Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.86% below the high.
Loading market information…
NASDAQ · TELA · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
TELA Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.67% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
TELA Bio, Inc.’s next earnings report is currently expected on Nov 10, 2026, with estimated earnings per share of -$0.19. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow TELA Bio, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:41 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 |
|---|
| May 8, 2025 |
| -$0.25-19.05% vs estimate |
| $18.52M+6.73% vs estimate |
| Q4 2024 | Mar 20, 2025 | -$0.23+4.17% vs estimate | $17.65M-16.15% vs estimate |
|---|
| Q3 2024 | Nov 7, 2024 | -$0.42-13.51% vs estimate | $18.96M-18.17% vs estimate |
|---|
THE ANALYST VIEW
8 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $2.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$21.45+$0.29 (+1.37%)
Cue Biopharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.86% below the high.
$46.82-$0.17 (-0.36%)
Spruce Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.71% below the high.
$0.49-$0.05 (-9.43%)
Outlook Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.57% below the high.
$2.66-$0.03 (-1.12%)
NRx Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.43% below the high.
$1.42$0.00 (0.0%)
Equillium, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.89% below the high.
$1.57+$0.01 (+0.64%)
Spectral AI, Inc.’s quoted price sits in the lower half of its reported 52-week range, 47.14% below the high.
$2.77-$0.05 (-1.77%)
Sensus Healthcare, Inc.’s quoted price sits in the lower half of its reported 52-week range, 49.54% below the high.
$10.99-$1.03 (-8.57%)
Coeptis Therapeutics Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.67% below the high.
